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Members of the vascular endothelial growth factor (VEGF) family of proteins are critical regulators of angiogenesis.
VEGF concentration gradients are important for activation and chemotactic guidance of capillary sprouting, but
measurement of these gradients in vivo is not currently possible. We have constructed a biophysically and molecularly
detailed computational model to study microenvironmental transport of two isoforms of VEGF in rat extensor
digitorum longus skeletal muscle under in vivo conditions. Using parameters based on experimental measurements,
the model includes: VEGF secretion from muscle fibers; binding to the extracellular matrix; binding to and activation of
endothelial cell surface VEGF receptors; and internalization. For 2-D cross sections of tissue, we analyzed predicted
VEGF distributions, gradients, and receptor binding. Significant VEGF gradients (up to 12% change in VEGF
concentration over 10 lm) were predicted in resting skeletal muscle with uniform VEGF secretion, due to non-uniform
capillary distribution. These relative VEGF gradients were not sensitive to extracellular matrix composition, or to the
overall VEGF expression level, but were dependent on VEGF receptor density and affinity, and internalization rate
parameters. VEGF upregulation in a subset of fibers increased VEGF gradients, simulating transplantation of pro-
angiogenic myoblasts, a possible therapy for ischemic diseases. The number and relative position of overexpressing
fibers determined the VEGF gradients and distribution of VEGF receptor activation. With total VEGF expression level in
the tissue unchanged, concentrating overexpression into a small number of adjacent fibers can increase the number of
capillaries activated. The VEGF concentration gradients predicted for resting muscle (average 3% VEGF/10 lm) is
sufficient for cellular sensing; the tip cell of a vessel sprout is approximately 50 lm long. The VEGF gradients also result
in heterogeneity in the activation of blood vessel VEGF receptors. This first model of VEGF tissue transport and
heterogeneity provides a platform for the design and evaluation of therapeutic approaches.
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Introduction
Vascular endothelial growth factor (VEGF) is a key
promoter of angiogenesis in vivo and it increases prolifer-
ation and migration of endothelial cells cultured in vitro [1].
In rats, there are ﬁve main splice variants of VEGF, denoted
120, 144, 164, 188, and 205 (corresponding to the number of
amino acids), and the 120 and 164 isoforms are the most
prevalent [2]. VEGF is expressed at different levels (ranging
over four orders of magnitude) by a variety of cells
throughout the body including skeletal muscle [3–5]. VEGF164
is secreted as a 45-kDa homodimeric glycoprotein containing
an exon-7 encoded domain which allows binding to heparin
and neuropilin-1 (NRP-1). VEGF120 is also a homodimeric
glycoprotein (36 kDa) but is missing the exon-7 encoded
domain. Because of this domain, only VEGF164 can bind to
the heparan sulfate proteoglycans (HSPG) present in high
concentrations in the extracellular matrix (ECM) and base-
ment membrane (BM) spaces, and the two splice variants are
responsible for different signaling in both physiological and
cancer angiogenesis [6,7]. Furthermore, due to the presence
of high concentrations of HSPG in the BM that surrounds
VEGF-secreting cells (such as skeletal muscle myocytes), a
large amount of VEGF164 becomes bound and sequestered
near sources of VEGF secretion, creating a steep VEGF
gradient [8]. The cellular response to VEGF occurs when
signaling is initiated by the binding of VEGF to its cell surface
receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF is
degraded after it is internalized by these two VEGF receptors.
The receptors and their interactions with VEGF and with
each other are discussed in depth in [9].
VEGF is involved in both physiological (e.g., during
exercise and wound healing) and pathological angiogenesis
(e.g., in ;60% of human tumors and in age-related macular
degeneration). VEGF upregulation is necessary for physio-
logical angiogenesis under conditions of hypoxia via oxygen-
sensing mechanisms in the HIF-1 pathway [10] and increased
Editor: Andrew S. Greene, Medical College of Wisconsin, United States of America
Received April 19, 2006; Accepted August 3, 2006; Published September 22, 2006
A previous version of this article appeared as an Early Online Release on August 3,
2006 (DOI: 10.1371/journal.pcbi.0020127.eor).
DOI: 10.1371/journal.pcbi.0020127
Copyright:  2006 Mac Gabhann et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Abbreviations: BM, basement membrane; EBM, endothelial basement membrane;
ECM, extracellular matrix; EDL, extensor digitorum longus; FGF, fibroblast growth
factor; HSPG, heparan sulfate proteoglycans; MBM, myocyte basement membrane;
MD, myonuclear domain; VEGF, vascular endothelial growth factor
* To whom correspondence should be addressed. E-mail: feilim@jhu.edu
PLoS Computational Biology | www.ploscompbiol.org September 2006 | Volume 2 | Issue 9 | e127 1107shear stress in blood vessels [11]. In rat extensor digitorum
longus (EDL) muscle during exercise, both hypoxia and
increased shear stress induce angiogenesis through over-
expression of VEGF by myocytes [12]. Because of the
importance of VEGF, many clinical trials are under way for
both pro- and anti-angiogenic therapies [13–15]. The FDA has
approved anti-VEGF treatments including Avastin (bevacizu-
mab), an antibody to VEGF, and Macugen (pegaptinib), an
RNA aptamer which binds to and sequesters human VEGF165.
Use of VEGF as a pro-angiogenic treatment for cardiac and
limb ischemia has generated intense interest but direct
administration of VEGF has not yet produced effective
results in humans, and initial trials of transplantation of
angiogenic cells have proven effective but require further
work [16–18].
To create an effective VEGF-driven pro-angiogenic ther-
apy, better understanding is needed of both physiological and
pathological VEGF-induced angiogenesis. Increasing VEGF
concentration leads to angiogenesis, but concentrations of
VEGF beyond critical levels may result in formation of
abnormal vessels (leaky, tumor-like, and with larger lumens)
and hemangiomas [19,20]. Thus, normal blood vessels can
only be formed if microenvironmental amounts of VEGF are
carefully maintained above threshold levels for therapeutic
angiogenesis but below threshold levels for abnormal angio-
genesis over a prolonged period of time. Furthermore,
responses to VEGF depend on not only VEGF concentration
but also VEGF gradients, which enhance VEGF-induced
angiogenesis and direct capillary growth [21–23]. Therefore,
it is not sufﬁcient to measure bulk quantities of VEGF in large
samples of tissue in order to predict angiogenic behavior.
In the present study, we constructed a computational
model to study extracellular diffusion of VEGF in vivo and
effects of VEGF upregulation on gradients and receptor
binding using the well-characterized rat EDL tissue as a
sample environment. We have previously constructed models
studying the kinetics of VEGF binding to receptors on cells in
vitro and the effect of the presence of NRP-1 or placental
growth factor [24,25]. We have also shown using Monte Carlo
methods that despite very small concentrations of free VEGF,
a continuum description in terms of VEGF concentrations is
justiﬁed [26]. Diffusion of VEGF in vitro has also been studied
using a computational model [21]. However, to our knowl-
edge, this is the ﬁrst model of VEGF diffusion in a geometri-
cally complex in vivo environment and it includes: transport
of the two most abundant VEGF isoforms through ECM and
BM, HSPG binding kinetics, VEGF secretion, and VEGF
receptor binding and internalization kinetics. NRP-1 was not
included in this model because there are currently no
available measurements of the amount of NRP-1 in skeletal
muscle. Using this model, we predict VEGF distribution and
analyze VEGF gradients at a resolution that is currently
impossible to measure experimentally. Use of this model will
aid in understanding mechanisms of physiological and
therapeutic VEGF overexpression. This model is general
and may be built upon in the future to include additional
molecular species as new experimental data are emerging,
e.g., neuropilin expression level in skeletal muscle; it can also
be applied to speciﬁc drug interactions and other tissue
types.
Results
Model Formulation
Model geometry. Rat EDL muscle geometry has been well-
characterized physiologically and in its responses to hypoxia,
hemodynamic shear stress, and electrical stimulation [11,27].
We have previously published a study of oxygen distribution
in EDL muscle as related to angiogenesis [28], and the present
study follows a similar methodology of geometric represen-
tation with several notable differences. A 2-D cross section of
muscle with an area of 200 3 208 lm
2 is represented by
regions of muscle ﬁbers and capillaries separated by
interstitial space (Figure 1). At the edges of the tissue area,
periodic boundary conditions for the molecular species
under consideration are applied, as this is a small piece of
tissue surrounded by the rest of the muscle. The dimensions
of the area were chosen so that no geometric discontinuities
would exist under these boundary conditions. Muscle ﬁbers
are explicitly represented in the present model as a separate
phase from the interstitial space and thus are boundaries for
VEGF transport. Based on photomicrographs [29] and
interstitial volume tracer experiments for rat skeletal muscle
[30], skeletal muscle ﬁbers were represented by circles for
simplicity, and they were staggered and packed in a uniform
fashion (Figure 1A). Each ﬁber has a diameter of 37.5 lm for a
cross-sectional area of 1,100 lm
2, consistent with experimen-
tal measurements [31]. A total of 30 ﬁbers were packed into
the cross section accounting for 79.6% of total cross-sectional
area.
Capillaries of 6 lm in external diameter and 0.5 lm wall
thickness (5 lm in lumen diameter) were added randomly
into the interstitial space between the muscle ﬁbers (Figure
1B). The endothelial cells that line these vessels express
VEGFR1 and VEGFR2 uniformly on their abluminal surface.
The placement of capillaries was constrained by a minimum
capillary-to-capillary distance parameter of 10 lm (measured
from the centers of the lumens) and a minimum capillary-to-
muscle-ﬁber distance of 1 lm (measured from the outer edge
of a capillary to the outer edge of a muscle ﬁber). A total of 33
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It is not currently possible to experimentally quantify the gradients
of protein concentration in the extracellular space in vivo. However,
the concentration gradients of vascular endothelial growth factor
(VEGF) are essential for both initiation and directed guidance of new
blood vessels. The authors develop a computational model of VEGF
transport in tissue in vivo (skeletal muscle, though the method is
applicable to other tissues and other proteins) with realistic
geometry and including biophysical interactions of VEGF, its
receptors, and the extracellular matrix. Using this model, the authors
predict for the first time the distribution of VEGF concentration and
VEGF receptor activation throughout the tissue. VEGF concentration
gradients are significant, up to 12% change in VEGF concentration
over 10 lm in resting muscle. Transplanting VEGF-overexpressing
myocytes (for therapeutic induction of blood vessel growth)
increases the gradients significantly. Endothelial cells in sprouting
vessels are approximately 50 lm long, and therefore the predicted
gradients across the cell are high and sufficient for chemotactic
guidance of the new vessels. The VEGF concentration gradients also
result in significant heterogeneity in the activation of VEGF
receptors on blood vessels throughout the tissue, a possible reason
for the sporadic nature of sprout initiation.
VEGF Distribution in Muscle and Angiogenic Therapycapillaries were placed randomly in the cross section. By
measuring the distance from random points in the tissue to
the center of the nearest capillary, we noted that our network
closely matches experimentally measured vascular distribu-
tion [32] (average distance 15.5 lm (our model) versus 15.9
lm (experimental); 95th percentile of distance 29.8 lm versus
28.6 lm). The geometrical model is consistent with exper-
imental observations of 800/mm
2 capillary density in resting
EDL [33]. The capillaries accounted for 2.2% of the cross-
sectional area, and the interstitial space totals 18.1% of the
cross-sectional area. All results presented here are for the
same arrangement of capillaries, except where a homogenous
capillary distribution is used and is so noted.
Each muscle ﬁber in the model is surrounded by a uniform
thin myocyte basement membrane (MBM) layer (Figure 1B).
Each capillary is surrounded by a uniform endothelial
basement membrane (EBM) layer. The two BM spaces are
separated by the ECM. The EBM and MBM each have distinct
thickness based on electron microscope measurements (84.8
nm and 31.7 nm, respectively [34]) and have lower diffusivity
and higher concentrations of HSPG than the ECM. Together,
the BM and ECM components form the interstitial space
within which VEGF diffuses.
Different units can be used to deﬁne each of the above
parameters; the units given in the glossary (Table 2) are
consistent with the equations presented below. The param-
eters may be converted to other units for comparison with
appropriate experimental data, for example, molecules/cell
or pmol/(lm
3 tissue). These conversions are achieved by using
the surface-area-to-tissue-volume ratios for myocytes (850
cm
2/cm
3) or blood vessels (150 cm
2/cm
3) in this tissue, and the
area of the cell (1,000 lm
2/endothelial cell; myocytes are
discussed later).
Transport calculations and reaction kinetics. In BM spaces,
the membrane thickness is no more than 85 nm, and
gradients across this distance are expected to be negligible,
therefore free VEGF concentration is assumed to be uniform
perpendicular to the capillary surface in the BM. Thus, at
endothelial cell surfaces, the free VEGF concentrations are
equal to those of its adjacent EBM spaces. VEGF that binds to
receptors comes from the adjacent EBM, and VEGF that
dissociates from receptors is released into the EBM; VEGF
expressed by myocytes is secreted into an adjacent MBM
space from which diffusion can then occur.
Transport within the ECM is described by mass balance
equations:
@½V120 =@t ¼ DV120r2½V120 ð 1Þ
@½V164 =@t ¼ DV164r2½V164  kon;V164;H½V164 ½HECM 
þ koff;V164H½V164HECM  ð2Þ
The mass balance equations describing VEGF transport
between ECM and MBM are:
@½V120 MBM=@t ¼ð sV120   Jout;V120Þ=dMBM ð3Þ
@½V164 MBM=@t ¼ð sV164   Jout;V164Þ=dMBM
  kon;V164;H½V164 ½HMBM 
þ koff;V164H½V164HMBM  ð4Þ
Here dMBM is the thickness of the MBM and Jout is the Fickian
diffusive ﬂux of VEGF from the BM to the ECM. At steady
state, the secretion of VEGF into the MBM and the diffusive
ﬂux of VEGF from BM to ECM are in equilibrium, but during
transients sV120 and Jout have different values.
The mass balance equations describing VEGF transport
between ECM and EBM are:
@½V120 EBM=@t ¼ð   Jout;V120   kon;V120;R1½V120 ½R1 
þ koff;V120R1½V120R1  kon;V120;R2½V120 ½R2 
þ koff;V120R2½V120 ½R2 Þ=dEBM
ð5Þ
@½V164 EBM=@t ¼  kon;V164;H½V164 ½HEBM þkoff;V164H½V164HEBM 
þð   Jout;V164   kon;V164;R1½V164 ½R1 
þ koff;V164R1½V164R1 
  kon;V164;R2½V164 ½R2 þkoff;V164R2½V164R2 Þ
=dEBM
ð6Þ
Here, dEBM is the thickness of the EBM.
Figure 1. Schematics of VEGF Transport in Skeletal Muscle
(A) Cross-sectional view of EDL tissue: red-filled circles represent muscle fibers, black unfilled circles represent capillaries located in the interstitium of
the tissue. The fibers are assumed to be regularly spaced and hexagonally packed.
(B) Interstitial space near a capillary: muscle fibers are surrounded by a thin MBM; capillaries formed by endothelial cells are surrounded by an EBM. The
ECM lies in between the EBM and MBM, and VEGF diffuses throughout the interstitial space.
(C) Diffusion and binding: two VEGF isoforms are secreted from the skeletal muscle myocyte into the MBM: VEGF120 and VEGF164 diffuse through the
MBM, EBM, and ECM, but only VEGF164 is able to bind with HSPG in each layer. Near the endothelial cell surface (located in the EBM), VEGF can interact
with VEGFR1 and VEGFR2, and both can be internalized whether bound to VEGF or unbound.
DOI: 10.1371/journal.pcbi.0020127.g001
PLoS Computational Biology | www.ploscompbiol.org September 2006 | Volume 2 | Issue 9 | e127 1109
VEGF Distribution in Muscle and Angiogenic TherapyOn the endothelial cell surface, the binding kinetics
between VEGF and receptors follows our previous study
[24] in which VEGF can be bound to receptors and both free
and bound receptors can be internalized. However, NRP-1
was not included in this model because it has not been
quantiﬁed in skeletal muscle. Equations 7–12 apply at the
surface of endothelial cells only because muscle ﬁbers are
assumed to express negligible amounts of VEGF receptors.
The VEGF concentrations in Equations 7–12 are the
concentrations in the EBM.
@½R1 =@t ¼ koff;V120R1½V120 ½R1 þkoff;V164R1½V164 ½R1 
 ð kon;V120;R1½V120 þkon;V164R1½V164 
þ kint;R1Þ½R1 þsR1 ð7Þ
@½R2 =@t ¼ koff;V120R2½V120R2 þkoff;V164R2½V164R2 
 ð kon;V120;R2½V120 þkon;V164;R2½V164 
þ kint;R2Þ½R2 þsR2 ð8Þ
@½V120R1 =@t ¼ kon;V120;R1½V120 ½R1 
 ð koff;V120R1 þ kint;V120R1Þ½V120R1  ð9Þ
@½V164R1 =@t ¼ kon;V164;R1½V164 ½R1 
 ð koff;V164R1 þ kint;V164R1Þ½V164R1  ð10Þ
@½V120R2 =@t ¼ kon;V120;R2½V120 ½R2 
 ð koff;V120R2 þ kint;V120R2Þ½V120R2  ð11Þ
@½V164R2 =@t ¼ kon;V164;R2½V164 ½R2 
 ð koff;V164R2 þ kint;V164R2Þ½V164R2  ð12Þ
Binding kinetics between VEGF and HSPG in the interstitium
is expressed as follows:
@½H =@t ¼ koff;V164H½V164H  kon;V164;H½V164 ½H ð 13Þ
@½V164H =@t ¼ kon;V164;H½V164 ½H  koff;V164H½V164H ð 14Þ
Here, [H] represents [HECM], [HMBM], and [HEBM]; [V164H]
represents [V164HECM], [V164HMBM], and [V164,HEBM] for bind-
ing reactions in the ECM, MBM, and EBM, respectively.
Thus, Equations 1, 2, 13, and 14 govern the concentration
of VEGF in the ECM, while Equations 3–6 and 7–12 together
form the boundary conditions at the myocyte cell surface
(Equations 3–4) and endothelial cell surface (Equations 5–12).
The notation in equations 1–14 is deﬁned in Table 2.
Model Parameters
The physiological parameters used in this model are
summarized in Table 1. Experimentally measured parameters
for VEGF transport in rat EDL are limited, and many
parameters were estimated from experiments performed on
rats and other species.
In vivo diffusivity calculations. VEGF diffusivity was
calculated using a molecular-weight–based relationship for
globular proteins [35] and adjusted to 37 8C using the Stokes–
Table 1. Parameters for VEGF Transport and Binding
Parameter Value Source
Diffusivity DV120 113 lm
2/s See text
DV164 104 lm
2/s See text
Internalization kint,R1,kint,R2 2.8 10
 4 s
 1 [24]
kint,V120R1,kint,V120R2,kint,V164R1,kint,V164R2 2.8 10
 4 s
 1 [24]
Insertion rate of receptors sR1 9.2 10
 16 pmol/lm
2/s See text
sR2 9.2 10
 16 pmol/lm
2/s See text
HSPG density HEBM,HMBM 1.3 10
 8 pmol/(lm
3 BM) [37]
HECM 7.5 10
 10 pmol/(lm
3 ECM) [37]
Binding kinetics kon,V120,R1,kon,V164,R1 31 0
10 pmol/lm
3/s [24]
kon,V120,R2,kon,V164,R2 11 0
10 pmol/lm
3/s [24]
koff,V120,R1,koff,V164R1 10
 3 s
 1 [24]
koff,V120,R2,koff,V164R2 10
 3 s
 1 [24]
VEGF secretion rate sV120 (basal) 2.95 10
 17 pmol/lm
2/s See text
sV164 (basal) 0.25 10
 17 pmol/lm
2/s See text
DOI: 10.1371/journal.pcbi.0020127.t001
Table 2. Glossary
Term Meaning
[V120],[V164] Concentrations of VEGF120 and VEGF164 (pmol/lm
3)
[R1],[R2] Concentrations of VEGFR1 and VEGFR2 (pmol/lm
2)
[V120R1],[V120R2]
Concentrations of VEGFR1 and VEGFR2 bound to VEGF120
(pmol/lm
2)
[V164R1],[V164R2]
Concentrations of VEGFR1 and VEGFR2 bound to VEGF164
(pmol/lm
2)
[H] Concentration of HSPG (pmol/lm
3)
[V164H] Concentration of VEGF164 bound HSPG (pmol/lm
3)
sR1,sR2
Insertion rate of surface species into endothelial cell membrane
(pmol/lm
2/s)
sV120,sV164
Secretion rate of VEGF120 and VEGF164 from muscle fibers
(pmol/lm
2/s)
kint Internalization rate of surface receptors and complexes (s
 1)
kon
Kinetic rate of binding of volumetric species to receptors or
HSPG (pmol/lm
3/s)
koff
Kinetic rate of dissociation of volumetric species from
receptors or HSPG (s
 1)
D Diffusivity (lm
2/s)
dMBM,dEBM Thickness of MBM and EBM (lm)
DOI: 10.1371/journal.pcbi.0020127.t002
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VEGF Distribution in Muscle and Angiogenic TherapyEinstein relation. We assume VEGF120 and VEGF164 aqueous
diffusivities of 142 and 133 lm
2/s. In skeletal muscle ECM,
VEGF diffusion is hindered by collagen ﬁbers (concentration:
75 mg/g ECM, ﬁber radius: 20 nm, ﬁber volume fraction: 0.14)
and glycosaminoglycan chains (concentration: 5 mg/g ECM,
ﬁber radius: 0.55 nm, ﬁber volume fraction: 7.8 10
 4) [36]. To
obtain in vivo values of diffusivity, we followed a method
previously outlined [37] to calculate diffusive hindrance in
interstitium. This predicts values of 113 and 104 lm
2/s for
VEGF120 and VEGF164 in vivo diffusivities, respectively.
HSPG and VEGF receptor density and kinetics. HSPG
concentration in ECM and BM spaces were obtained from
values measured in human myocardium [37]. Currently, no in
vivo measurements are available for the HSPG population in
skeletal muscle. Effective VEGF–HSPG binding kinetics in
vivo has not been measured, so we use those determined for
the ﬁbroblast growth factor (FGF-2). In vitro studies conﬁrm
that binding kinetics is similar for reactions of FGF-2 and
VEGF binding to HSPG [38].
VEGF receptor concentrations and kinetic rates were
chosen based on in vivo measurements of total VEGFR2
protein concentration and capillary density in human vastus
lateralis skeletal muscle [39,40]. For that tissue, total protein
concentration in skeletal muscle is assumed to be 150 mg/g
muscle [41], endothelial cell surface area is 1,000 lm
2, and
capillary diameter is 7 lm. The in vivo measurements
correspond to an average VEGFR2 density of 20,000
receptors per cell, which is of the same order of magnitude
as previously measured in vitro values of 50,000 [24].
However, no study has determined the percentage of total
VEGF receptors expressed on the abluminal capillary surface,
within the cell, and on the luminal cell surface. In this study,
we assume as a baseline that 50% of total receptors (10,000
VEGFR2/cell) is expressed on the abluminal cell surface
(available for VEGF binding), and we perform a sensitivity
analysis to study the effects of expressing more or fewer
receptors.
In vivo measurements in human show that approximately
ten times as much VEGFR1 is expressed as VEGFR2 [39,40].
However, soluble VEGFR1 (sVEGFR1) is also present in
interstitial spaces of skeletal muscle (not included in this
model), and no studies in skeletal muscle have reported the
ratio of VEGFR1 to sVEGFR1. In our study, we assume that an
equal amount of VEGFR1 is expressed on the abluminal
extracellular surface as VEGFR2, and we have also performed
sensitivity analyses to study the effect of changing VEGFR1
and VEGFR2 cell surface concentrations on the formation of
VEGF gradients. VEGF receptor kinetic rates obtained from
in vitro binding studies [24] were assumed to hold in vivo.
Estimates of VEGF expression. Currently, only in vitro
measurements of VEGF protein secretion have been pub-
lished [3,42]. In addition, measurements of total VEGF in rat
includes VEGF located intracellularly [11] and bound VEGF,
which is sensitive to HSPG and sVEGFR1 concentrations. To
simulate realistic in vivo conditions, expression rates for
VEGF120 and VEGF164 were obtained by adjusting values so
that our model matches experimental in vivo measurements
of unbound VEGF in human skeletal muscle [43]. Under pre-
and post-exercise resting conditions, unbound VEGF con-
centrations range between 0.6 and 1.5 pM, so in our study we
target a free concentration of approximately 1 pM under
resting conditions. Under basal conditions (to meet the
requirement of 1 pM free VEGF concentration), muscle ﬁbers
express VEGF at a rate of 3.2 10
 17 pmol/lm
2/s (2.7 fmol/(L
tissue)/s), though different receptor densities would require
different secretion rates to achieve the same protein
concentration.
Skeletal myocytes are multinucleate cells, hence they
cannot be directly compared with the mononucleate cells
used to measure VEGF secretion in vitro experimentally. The
myonuclear domain (MD) is the volume and associated cell
membrane surface area corresponding to (and under the
control of) each nucleus of the cell. To make a valid
comparison, secretion from this surface area is assumed to
be under the control of a single nucleus. By counting the
number of nuclei per unit length of the ﬁber, and the cross-
sectional area, the ﬁber surface area of each MD was shown to
decrease with the cross-sectional area of the ﬁber [44]. For a
cylindrical ﬁber with a diameter of 37.5 lm, the predicted MD
surface area in rat muscle is approximately 2500 lm
2. The
VEGF secretion rate used in our model corresponds to 0.048
molecules/MD/s and secretion from each MD can be
compared with that from a mononucleate cell. The secretion
rate in our model is comparable to in vitro measurements in
various tissues including rat skeletal muscle: 0.01 in rat tibialis
anterior [45], 0.08 in rat adipocyte [46], and 0.10 in rat
cavernous smooth muscle [47] (all in molecules/cell/s). Studies
have demonstrated that VEGF secretion rates range over four
orders of magnitude between normal and tumor tissue (0.001
versus 11.6 molecules/cell/s) [3,5]. Furthermore, cell-based
pro-angiogenic therapies have been studied using transgenic
myoblasts expressing VEGF at levels between 20-fold and 200-
fold basal (0.85 to 9.3 molecules/cell/s for different transgenic
clones) [19,20].
Using relative mRNA abundances for splice variants of
V E G Fi nm o u s es k e l e t a lm u s c l e[ 2 ] ,a s s u m i n gal i n e a r
relationship between VEGF protein secretion and mRNA
levels [10] and only these two isoforms present, VEGF164
secretion is nearly 12 times higher than VEGF120 secretion
(2.95 versus 0.25 10
 17 pmol/lm
2/s, or 0.044 versus 0.004
molecules/MD/s). Both isoforms are secreted by the myocytes.
Results of Computer Simulations
Basal conditions—Uniform VEGF secretion. Under resting
physiological conditions, each skeletal muscle ﬁber is
assumed to secrete VEGF at the same rate because all muscle
ﬁbers are well-oxygenated. The uniform secretion simulation
results are summarized in Figure 2. The total VEGF content
in muscle (free, bound to HSPG, and bound to cell surface
receptors; not including intracellular VEGF, e.g., inside
muscle ﬁbers) is predicted to be 693 pg/(cm
3 tissue). Of total
VEGF, 50% is bound to endothelial cell receptors (VEGFR1:
37%, VEGFR2: 13%), 49% is bound to HSPG (ECM: 36%,
MBM: 9%, EBM: 4%), and 1% exists as freely diffusible VEGF.
Of free VEGF, 7% is VEGF120 and the other 93% is VEGF164.
The concentration of total (bound and free) VEGF is 17.5-fold
higher in the MBM and 16.6-fold higher in the EBM
compared with the ECM due to the higher concentration of
HSPG in BM. On the endothelial cells, 2.3% of VEGFR1 and
0.8% of VEGFR2 is occupied by VEGF, corresponding to
approximately 230 and 80 molecules bound per cell,
respectively.
Under conditions of uniform secretion, relative VEGF
gradients average 3.0% VEGF/10 lm and reach a maximum of
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VEGF Distribution in Muscle and Angiogenic Therapy12.2% VEGF/10 lm in the ECM (relative gradients are
measured as change in VEGF concentration across 10 lm,
divided by mean VEGF tissue concentration); the scale of 10
lm is chosen as relevant to endothelial cell sensing of
chemotactic gradients during sprout formation. VEGF con-
centrations and an analysis of gradients are visualized in
Figure 2A. The most signiﬁcant gradients exist between
interstitial space with a high local capillary density and an
area with low density, indicating that existence of VEGF
gradients is dependent on heterogeneous placement of
capillaries. When the capillaries are spaced homogeneously
(30 capillaries are required for this), VEGF gradients decrease
to an average of 1.3% VEGF/10 lm and a maximum of 3.7%
VEGF/10 lm (Figure 3A).
Effect of VEGF receptor and HSPG concentration on VEGF
gradient formation. When HSPG binding afﬁnity was
increased to 10-fold basal value (by increasing kon,V164,H), or
the concentrations of HSPG in ECM, EBM, and MBM were all
increased 10-fold, the total VEGF concentration in interstitial
space increased 10-fold but surface receptor binding and
Figure 2. VEGF Distribution in Resting Skeletal Muscle for Uniform Secretion of VEGF
(A) VEGF concentration variations in skeletal muscle. The surface represents the total VEGF concentration (free plus HSPG-bound) across the interstitial
space.
(B) Graphical representation of VEGF binding: large gray circles represent muscle fibers. Small circles represent capillaries and are color-coded to show
the amount of VEGF bound to the surface of the capillary.
(C) Histogram of average VEGF binding to capillaries. Each capillary has a different amount of bound VEGF due to the spatial variations of VEGF. Some
capillaries may be activated while others are not.
(D) Histogram of VEGF gradients. The percentage of tissue that experiences VEGF gradient of a certain magnitude. Gradient is defined as the change in
VEGF concentration over 10 lm divided by the mean VEGF concentration in the tissue. Capillary distribution in subsequent figures (except Figure 3A) is
the same as Figure 2.
DOI: 10.1371/journal.pcbi.0020127.g002
Figure 3. Effect of VEGF Capillary Distribution and HSPG on VEGF Gradients
(A) Uniform capillary distribution results in a decrease in the average VEGF gradients in the tissue.
(B,C) VEGF gradients at steady state are invariant (in percentage terms) to changes in the extracellular matrix composition. Increased density or affinity
of VEGF binding sites results in increased bound VEGF content (and thus increased absolute values of the gradient), but no change in the relative
gradient.
DOI: 10.1371/journal.pcbi.0020127.g003
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VEGF/10 lm) (Figure 3B and 3C). Absolute values of
concentration gradients (e.g., in pM per lm) would obviously
be increased due to the increased average concentration.
However, at steady state the HSPG in the matrix does not
affect the relative gradient.
To study the effect of changing VEGF receptor concen-
trations on VEGF gradient formation, VEGF secretion levels
were changed to maintain a mean unbound VEGF concen-
tration of 1 pM. Decreasing VEGFR1 and VEGFR2 insertion
rates to 20% each effectively decreases cell surface receptor
concentrations to approximately 2,000 receptors/cell each
(Figure 4A). This decreases VEGF gradients to an average of
2% VEGF/10 lm and also shifts the majority of VEGF from
the cell surface to the interstitial space (from 49% to 88% of
total VEGF; at 20% VEGF secretion). Doubling each VEGF
receptor insertion rate corresponds to all VEGF receptors
being expressed on the abluminal surface of endothelial cells
(20,000 receptors/cell each). This nearly doubles maximum
gradient (22.0% VEGF/10 lm) and increases the average
gradient to 4.1% VEGF/10 lm (at 2-fold VEGF secretion).
When VEGF receptor insertion rate is increased 10-fold to
represent tissues with 10-fold receptor expression compared
with the standard parameters (100,000 receptors/cell for
VEGFR1 and VEGFR2), maximum VEGF gradient increases
nearly 5-fold (63.4% VEGF/10 lm) and average gradient
increases to 10.5% VEGF/10 lm (at 10-fold VEGF secretion).
Altering the ratio of VEGFR1 to VEGFR2 cell surface
insertion rates follows the same trend (Figure 4B). If no
VEGFR1 is expressed on the cell surface, VEGF gradients
reduce to an average of 2.2% VEGF/10 lm (at 26% VEGF
secretion). Conversely, increasing VEGFR1 cell surface
expression 10-fold (representing a 10-to-1 cell surface
expression of VEGFR1; 100,000 VEGFR1 and 10,000
VEGFR2/cell) increases gradients to 9.1% VEGF/10 lmo n
average (at 8-fold VEGF secretion). Overall, increasing VEGF
receptor expression will increase VEGF gradients and require
higher total VEGF secretion rates to maintain constant VEGF
content in the tissue.
Binding and internalization kinetics sensitivity analysis.
When VEGF receptor afﬁnity is increased 10-fold, VEGF
gradients increase to an average of 9.8% VEGF/10 lm and a
maximum of 60.1% VEGF/10 lm (Figure 5A). The change in
afﬁnity reduces the amount of interstitial VEGF required to
achieve the same quantity of VEGF bound on the cell surface
and the same rate of VEGF internalization. Increasing VEGF
receptor internalization rate 10-fold similarly reduces the
amount of bound VEGF (and therefore free VEGF) required
to achieve the same level of total VEGF internalization. Total
VEGF receptor concentrations (free and bound) are main-
Figure 4. VEGF Receptor Density Alters Magnitude of VEGF Gradients
Increasing VEGFR2 density (A) and increasing VEGFR1 density (B) increase the gradients of VEGF concentration in tissue. Surfaces represent
concentration of total VEGF (pM, free plus HSPG-bound) in the ECM across the cross section of tissue. Histograms of VEGF gradients and the percentage
of tissue involved. Gradient defined as in Figure 2.
DOI: 10.1371/journal.pcbi.0020127.g004
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Gradients increased to an average of 4.8% VEGF/10 lm and
a maximum of 25.4% VEGF/10 lm (Figure 5B). Our study
shows that VEGF gradients are highly dependent on cell
surface receptor binding afﬁnity and internalization rates for
which there are no direct in vivo measurements available.
However, the trends show that increasing either receptor
binding afﬁnity or internalization rate (while maintaining
receptor density) will increase VEGF gradients and reduce
the interstitial level of VEGF necessary to achieve the same
quantity of bound VEGF. In skeletal muscle, NRP-1 expres-
sion has not been measured, and therefore we have not
included it explicitly. The presence of NRP-1 would effec-
tively increase the afﬁnity of VEGFR2 and decrease the
afﬁnity of VEGFR1 for VEGF164, so its net effect on VEGF
gradients depends on the relative expression of the two
receptors.
Uniform VEGF upregulation. VEGF expression is upregu-
lated 4-fold in exercise [39] and 6-fold in chronic electrical
stimulation [10] protocols. Uniformly increasing VEGF
secretion rates 10-fold in all muscle ﬁbers in the simulations
results in a linear response in increases of both free and
bound VEGF concentration (Figure S1). Between basal
secretion and 10-fold VEGF overexpression, total VEGF
concentration increased from 0.7 to 7.6 ng/(cm
3 tissue) (11-
fold increase). The fractional occupancy of VEGFR1 in-
creased 9.6-fold (2.3% to 22.1%) and that of VEGFR2
increased 12-fold (0.8% to 9.6%). Free and bound VEGF in
the interstitium increase proportionally, so absolute VEGF
gradients (change in VEGF concentration over a distance)
also increase proportionally. Relative VEGF gradients (i.e.,
gradients normalized by mean VEGF concentration in the
interstitial space), are the same as the gradients under basal
conditions (average of 3% and maximum of 12% VEGF/10
lm) (Figure S2).
Under uniform secretion, the bound VEGF concentration
on capillaries ﬁts an approximately normal distribution with
a mean and standard deviation of 511 and 26.1 10
 7 pmol/
cm
2, respectively (Figure 2C). When VEGF is uniformly
overexpressed, the bound VEGF concentrations increase
and continue to ﬁt a tight normal distribution as in basal
conditions with a mean of 5112 and standard deviation of 194
10
 7 pmol/cm
2.
Single and multiple ﬁber upregulation. To predict the
impact of cell-based therapy in delivering VEGF to muscle,
we examined the effects of overexpression in one ﬁber versus
distributed overexpression. Speciﬁc muscle ﬁbers were
chosen to chronically overexpress VEGF such that the
number and spatial positions of overexpressing ﬁbers varied
while total secretion in the tissue was kept constant. Six
conditions were studied: single ﬁber at 40-fold overexpres-
sion, two adjacent ﬁbers at 20-fold, two distant ﬁbers at 20-
fold, three adjacent ﬁbers at 13.3-fold, three distant ﬁbers at
13.3-fold, and uniform secretion at 1.3-fold above basal level
(while remaining ﬁbers secrete at basal level), and the results
are summarized in Figure 6.
Total VEGF increases equally in all cases but much larger
gradients are generated by local overexpression. Under
single-ﬁber 40-fold overexpression (Figure 6A), VEGF gra-
dients average 4.3% VEGF/10 lm and reach a maximum of
44.1%/10 lm (43% and 261% higher than uniform expres-
sion, respectively). For overexpression in two ﬁbers at 20-fold
over basal level (Figure 6C and 6D), VEGF gradients are
sensitive to the spatial distribution of overexpressing ﬁbers.
Adjacently placed overexpressing ﬁbers produce VEGF
gradients averaging 3.9% VEGF/10 lm reaching a maximum
of 33.1% VEGF/10 lm, while distantly placed ﬁbers (106 lm
between the centers of the ﬁbers) average 3.2% VEGF/10 lm
and reach a maximum of 20.6% VEGF/10 lm. For three-ﬁber
overexpression at 13.3-fold over basal level (Figure 6E and
6F), the results follow the trend of two-ﬁber overexpression.
Three adjacent overexpressing ﬁbers produce gradients
averaging 3.6% VEGF/10 lm at a maximum of 28.3% VEGF/
10 lm, while three distant overexpressing ﬁbers (106 lm
between the centers of the ﬁbers) produce gradients averag-
ing 3.2% VEGF/10 lm at a maximum of 14.2% VEGF/10 lm.
The differences in VEGF gradients for the overexpression
models directly affect cell surface receptor VEGF binding.
For single-ﬁber overexpression (Figure 6A, Figure 7), the
three capillaries adjacent to the overexpressing ﬁber bind up
to 2,050 10
 7 pmol/cm
2 of VEGF while all other capillaries
bind a maximum of 1,609 10
 7 pmol/cm
2 (27% difference).
Figure 5. Effect of VEGF Receptor Kinetics on VEGF Gradients
(A) Increased binding affinity (increased on-rate) has a similar outcome to increases in the receptor density: the VEGF gradients are magnified.
(B) Increased internalization rate of VEGF-receptor complexes results in an increase in the VEGF gradients.
DOI: 10.1371/journal.pcbi.0020127.g005
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ﬁber (20 capillaries) bind a maximum of 1,242 10
 7 pmol/cm
2
(65% difference). For overexpression in two or three ﬁbers,
adjacent overexpression produces larger heterogeneities in
capillary VEGF binding (standard deviation: 272 and 260
versus 190 and 104 10
 7 pmol/cm
2, respectively) and higher
maximum capillary bound VEGF (1,790 and 1,761 versus
1,577 and 1,385 10
 7 pmol/cm
2, respectively) and over-
expression in three distant ﬁbers produces maximum
capillary VEGF binding near uniform levels (1,385 versus
1,342 10
 7 pmol/cm
2).
Overexpression from a single ﬁber produces a distinct
threshold of VEGF binding between capillaries adjacent to
overexpressing ﬁbers and non-adjacent capillaries (Figure 7).
As the number of overexpressing ﬁbers is increased while
total secretion is held constant, the distinction between VEGF
bound to adjacent and non-adjacent capillaries becomes less
apparent (Figure 7), and spatial distribution of overexpress-
ing ﬁbers affects VEGF gradients and greater distances
between overexpressing ﬁbers produces a far more uniform
response with smaller gradients (Figure 6).
Effect of overexpression density—Increasing total VEGF
secretion. To determine the effect of increasing the total
VEGF dose delivered to the tissue, we change the density of
VEGF-expressing ﬁbers. One, two, or three muscle ﬁbers were
each chosen to overexpress VEGF at 40-fold over basal level
to study the effect of overexpression density on VEGF
distribution (Figures 8 and 9). For overexpression of three
adjacent ﬁbers, gradients average 5.6% VEGF/10 lm (36%
VEGF/10 lm maximum), and capillaries can bind up to 4,087
10
 7 pmol/cm
2 of VEGF (versus 2,049 10
 7 pmol/cm
2 for
single-ﬁber overexpression). Choosing distant overexpressing
ﬁbers as in Figure 8B and 8E (106 lm between the centers of
the ﬁbers) decreases both gradients (average 3.6, maximum
33% VEGF/10 lm) and maximum capillary VEGF binding
(3,022 10
 7 pmol/cm
2). Decreasing the number of over-
Figure 6. Cell-Based Delivery of VEGF to Muscle
The total VEGF expression in each of the tissues (A–F) is the same; the arrangement delivery of VEGF from cells incorporated into each tissue is different.
Stars mark the fiber(s) that overexpress VEGF. VEGF gradients and capillary activation graphs are as for Figure 2.
(A) 40-Fold overexpression of VEGF in one fiber.
(B) Uniform 1.33-fold overexpression of VEGF by all fibers.
(C,D) 20-Fold overexpression of VEGF in two fibers, close together (C) or distant (D).
(E,F) 13.3-Fold overexpression of VEGF in three fibers, close together (E) or distant (F).
DOI: 10.1371/journal.pcbi.0020127.g006
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expression) does not directly correlate with a decrease in
VEGF gradients (5.1% and 4.2% VEGF/10 lm average for two
adjacent ﬁbers and single ﬁber, respectively), but maximum
capillary-bound VEGF decreases (2,963 and 2,590 10
 7 pmol/
cm
2 for two adjacent ﬁbers and single ﬁber, respectively) due
to the decreased total VEGF expression in the tissue.
Discussion
This study establishes a conceptual framework for the study
and prediction of VEGF gradients in tissue, which cannot be
measured with present experimental techniques. The effects
of VEGF on angiogenesis are widely studied, and experiments
have shown that VEGF gradients are necessary for endothelial
tip cell migration and guidance during sprouting angio-
genesis to prevent malformation of microvasculature [21–23].
Our model predicts that signiﬁcant gradients (average 3%
VEGF/10 lm; greater than 10% in part of the tissue) develop
at the scale of the single endothelial cell even under resting
conditions. For sprouting vessels, the tip cell is approximately
50 lm long; the gradients are thus sufﬁcient for cell sensing.
No study has yet determined whether the endothelial tip cell
senses and responds to relative or absolute gradients of VEGF
(e.g., in chemotaxis). Our study reports relative gradients in
units of percent VEGF/10 lm, but these can be converted to
absolute gradients by multiplying the relative value by the
mean VEGF concentration in the tissue.
The gradients of VEGF concentration result in signiﬁcant
heterogeneity in the binding of VEGF to VEGF receptors on
the capillaries; this may be a reason for the stochasticity of
sprout formation—some capillaries become angiogenically
active, while others do not. In addition, non-uniform over-
expression of VEGF leads to increased gradients and to a
different pattern of capillary activation by VEGF compared
with uniform overexpression.
Our model is constructed from published rat EDL skeletal
muscle data, but parameters such as binding afﬁnity of
receptors have never been measured in vivo and others such
as free VEGF concentration have never been measured
speciﬁcally for rat EDL tissue. Receptor expression on
endothelial cells has not been measured for rat EDL so our
model uses measurements for human skeletal muscle, and we
assumed that the same number of receptors per endothelial
cell is expressed in human and rat. Our sensitivity analysis of
the effect of VEGF receptor concentration on the formation
of VEGF gradients predicts that gradients will be smaller if
receptor expression is lower in rat than human. Also, we have
previously shown that the presence of NRP-1 has a strong
effect on VEGF binding kinetics [24], but NRP-1 expression
has never been measured in rat skeletal muscle. We predict
that VEGF gradients would still be signiﬁcant in the presence
of NRP-1 but the response would depend on the concen-
trations of VEGFR1 and VEGFR2 in the muscle. Furthermore,
an interesting conﬂict arises regarding the void volume
(fraction of interstitial space). Radiotracer data for rat
skeletal muscle gives values near 18% [30], while analysis of
micrographs reveals much lower values ranging from 5%–
10% [11]. The discrepancy remains unresolved, and we used
the tracer data for our model.
Our analyses of both VEGF receptor quantity and receptor
binding kinetics can also be interpreted as alternative model
parameters for different tissues types or demonstrate the
response of VEGF gradients to a change in muscle state (e.g.,
increase in VEGFR2 in response to exercise [48]). Our study
shows VEGF gradients in tissue are dependent on VEGF
receptor concentrations, and increasing receptor expression
on endothelial cells (while keeping binding kinetics constant)
results in steeper gradients. By doubling surface expression of
VEGFR1 and VEGFR2, maximum gradients nearly double;
thus the tissue has the ability to modulate gradients based on
cellular expression. Furthermore, recent evidence suggests
that skeletal myocytes may also express VEGF receptors,
which may have a direct effect on PI3K/Akt signaling (shown
to induce the expression of VEGF in both endothelial and
non-endothelial cells) [49,50]. The amount of myocyte surface
receptor expression has not been quantiﬁed and its effect on
gradients was not predicted in this study.
Both total and unbound VEGF concentrations have been
measured in vivo [10,42], and localization of VEGF has been
shown through VEGF staining and microscopy [11]. In our
study, we report that the total VEGF content in muscle (free,
bound to HSPG, and bound to cell surface receptors) is
predicted to be 693 pg/(cm
3 tissue) under control conditions.
This is approximately 0.4% and 2% of experimentally
measured whole tissue VEGF concentration for skeletal
muscle in human and rat, respectively [3,39]. A portion of
remaining VEGF may be distributed within myocytes, and
Figure 7. VEGF Binding to Capillaries for Cell-Based Delivery of VEGF to
Muscle
Each vessel in each tissue experiences a different level of VEGF binding.
Total VEGF expression level is the same in each tissue, and the mean
VEGF binding to capillaries is the same, but the concentrating of VEGF
overexpression into a small number of adjacent fibers results in increased
variability of binding. The tissues are arranged in decreasing order of
standard deviation of VEGF-capillary binding, as a metric of the variability
in capillary activation within the tissue. The more concentrated the VEGF
overexpression, the higher the variability. Each tissue is labeled with the
number of fibers overexpressing VEGF, the level of overexpression in
each fiber, and the panel in Figure 6 for the corresponding VEGF
concentration and receptor activation. The shaded bars in the bottom
graph represent VEGF binding to capillaries under basal (no over-
expression) conditions.
DOI: 10.1371/journal.pcbi.0020127.g007
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VEGF Distribution in Muscle and Angiogenic Therapythis intracellular content has not yet been quantiﬁed in
experimental studies. Furthermore, soluble VEGFR1
(sVEGFR1) has not been included in our model, and HSPG
concentration in interstitium varies between different skel-
etal muscle types. Increasing the amount of either HSPG or
sVEGFR1 would increase predicted total VEGF in tissue. Our
study focuses on VEGF gradients and our results show that
neither HSPG concentration nor level of uniform VEGF
expression affects the relative gradients.
Currently, there are no measurements of VEGF receptor
binding or VEGF distribution in vivo. Our model predicts
that approximately half of total VEGF is bound to the cell
surface receptors and that less than 3% of VEGF receptors
(both VEGFR1 and VEGFR2) are occupied. VEGF in the
interstitium is essential to the guidance of capillary sprouts
during angiogenesis, and only 2.5% of interstitial (non- cell
surface–bound) VEGF is freely diffusible. It is unknown
whether HSPG-bound VEGF plays a direct role in guiding
capillary sprouts, but studies show that heparin-binding
isoforms of VEGF are essential to proper vessel formation
[23]. Our model shows that under steady state conditions,
relative gradients of free VEGF (measured as a change in free
VEGF over distance divided by mean free VEGF) match
relative gradients of bound VEGF in the ECM.
The low fractional occupancy of VEGF receptors on
endothelial cells indicates that in resting skeletal muscle,
approximately 310 molecules of VEGF are bound per cell on
average. Endothelial cells may use a system of VEGF signaling
ampliﬁcation to produce angiogenic events. Despite these
small quantities of bound VEGF, we have previously shown
through Monte Carlo simulations that a continuum model
gives valid results for VEGF interactions [26]. The high
fraction of unbound receptors in resting skeletal muscle gives
the cell the ability to internalize large amounts of VEGF and
may provide increased sensitivity to changes in extracellular
VEGF concentrations or gradients.
Our sensitivity analysis shows that VEGF gradients are
highly sensitive to parameters for VEGF receptor kinetics and
concentration values. In our model, HSPG concentration and
binding kinetics do not affect relative gradients, and
increasing HSPG concentration causes more VEGF to be
bound without affecting free VEGF content. Experiments
show that HSPG has a signiﬁcant effect on the mitogenic
activity of VEGF [51] and modulates interactions between
VEGF and its receptors [52]. Furthermore, HSPG reduces
degradation of other signaling molecules such as bFGF [53].
Changing VEGF receptor concentrations (by changing VEGF
receptor insertion rate or changing internalization rates),
binding afﬁnity, internalization kinetics, or heterogeneity of
capillary placement has a signiﬁcant effect on VEGF
gradients. These kinetic rates and concentrations must be
better characterized in vivo and in more tissues in order to
make more accurate predictions of VEGF gradients.
Our model shows that even under resting physiological
conditions, VEGF gradients of up to 12% VEGF/10 lm can
exist throughout skeletal muscle. The gradients exist due to
the spatial heterogeneity of capillaries within the tissue. When
capillaries are uniformly spatially distributed, gradients do
not exceed 4% VEGF/10 lm at any location. The model’s
random capillary placement is typical of capillary distribution
Figure 8. Increasing Dose of Cell-Based VEGF Delivery
The delivery of two or three fibers overexpressing VEGF 40-fold is compared with an equivalent uniform overexpression.
(A,B) VEGF concentration and gradients for three 40-fold overexpressing fibers close together (A) or distant (B).
(C) Uniform VEGF overexpression of 4-fold.
(D,E) VEGF concentration and gradients for two 40-fold overexpressing fibers close together (D) or distant (E).
(F) Uniform VEGF overexpression of 2.67-fold.
DOI: 10.1371/journal.pcbi.0020127.g008
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be highest in areas with few capillaries, but deviations in
bound VEGF are small between capillaries (mean 610%).
These differences may be signiﬁcant for capillary sprouting;
the threshold in VEGF receptor activation between sprouting
and not sprouting is not known. VEGF concentration
increases linearly with total secretion, and the concentration
of bound VEGF increases linearly for all capillaries.
Our model predicts the angiogenic effect of VEGF using the
density of bound VEGF receptors on capillaries as an
indication of the probability of capillary proliferation or
activation which leads to angiogenesis. Because VEGF
receptor binding has low heterogeneity (i.e., low standard
deviation) under uniform expression (Figures 2, 7, and 9),
most capillaries will be activated to the same degree. That is, if
a threshold level of VEGF signaling triggers angiogenic
sprouting, most capillaries will exceed (or fall below) the
threshold and respond (or not respond) together. For uniform
overexpression to stimulate angiogenic sprouting in only a
small fraction of the vessels, other distinct intracellular and
intercellular signals should ultimately govern where sprout
formations occur. It is possible that heterogeneous oxygen
distribution under certain conditions, e.g., in exercise, leads to
heterogeneity of VEGF secretion via the hypoxia-inducible
factor HIF-1a; this scenario should be explored in future
studies. For non-uniform overexpression, a subset of capil-
laries has more VEGF–VEGFR complexes than the others
(Figures 7 and 9). Thus, that fraction of the vessels may be
activated and initiate angiogenic sprouts while the other
vessels do not. For example, for an activation threshold of
2,000 10
 7 pmol/cm
2, three vessels will be activated for the case
of a single 40-fold overexpressing ﬁber (Figure 7) while no
vessels will be activated in other distributions.
Local overexpression simulations (where only one to three
ﬁbers overexpress VEGF) follow experimental observations of
transgenic myocyte transplants [19,20]. In those studies,
transgenic myocytes overexpress VEGF at levels between 20-
fold and 200-fold, which lead to either normal or aberrant
(malformed) angiogenesis. The results of our model support
experimental observations for both transgenic myoblasts and
exercising muscle that VEGF upregulation is necessary for
angiogenesis but total dosage of VEGF is insufﬁcient for
growth of stable vessels [11,19]. Our model shows that when
three adjacent overexpressing VEGF myocytes (at 40-fold
expression each) are placed in tissue, surrounding capillaries
bind nearly eight times as much VEGF (compared with basal
level). The diffusion of VEGF through interstitial space is not
fast enough to prevent speciﬁc capillaries adjacent to over-
expressing myocytes from becoming activated more than
others. Therefore, decreasing the number of overexpressing
myocytes will not prevent small areas of tissue from
developing hemangiomas due to the synergistic activation
of capillaries by several adjacent myocytes (in agreement with
[19]). Conversely, decreasing the maximum secretion by a
single myocyte will decrease the maximum capillary activa-
tion independent of the number of adjacent overexpressing
myocytes. Furthermore, the activation of speciﬁc capillaries
(e.g., one-third of all capillaries binding up to 65% more
VEGF than other capillaries for a single 40-fold overexpress-
ing ﬁber; Figure 7) may produce a different pattern of
angiogenesis compared with nearly uniform capillary activa-
tion resulting from uniform VEGF expression. Because
microenvironmental gradients cannot be externally con-
trolled in vivo, in order for transgenic myocytes to be an
effective tool for therapeutic angiogenesis, the level of VEGF
overexpression may instead be carefully controlled for each
myocyte. Although experiments have also shown that
myoblasts expressing VEGF165 up to 20-fold of basal level
can be implanted into heart muscle damaged by myocardial
infarction resulting in angiogenesis, improved circulation,
and no hemangioma formation [54], the safety of VEGF
overexpression therapy is still questioned [55]. Therefore,
more experimental studies are needed for a more compre-
hensive understanding of normal versus aberrant VEGF-
induced angiogenesis.
Our model provides a framework for future models to
study VEGF gradients, and can be applied to hosts of other
physiological and drug-induced conditions (including exer-
cise, ischemia, and VEGF pellet administration), as well as to
other tissues (including tumor). The 2-D model can be
extended to a 3-D model in order to analyze longitudinal
VEGF gradients at the cost of computational complexity. This
study also provides a valuable tool to biologists by raising
questions concerning both the importance of intracellular
VEGF signaling and biophysical changes to the tissue
environment when stress is applied to tissue. Many questions
still remain unanswered such as whether large quantities of
VEGF receptors are expressed on myocytes or on the
intraluminal surface of capillaries. These key questions may
Figure 9. VEGF Binding to Capillaries for Increasing VEGF Dose
The distribution of VEGF binding on vessels for one, two, and three 40-
fold overexpressing fibers, and the equivalent uniform overexpression.
Each tissue is labeled with the number of fibers overexpressing VEGF, the
level of overexpression in each fiber, and the panel in Figure 8 for the
corresponding VEGF concentration and receptor activation.
DOI: 10.1371/journal.pcbi.0020127.g009
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valuable insight into the complexity of VEGF signaling and
interactions with other pro- and anti-angiogenic factors.
In summary, the key ﬁndings of this study are: signiﬁcant
VEGF gradients are predicted to exist in tissue in vivo,
sensible at the single-cell level; VEGF concentration gradients
lead to blood vessel VEGF receptor activation heterogeneity;
VEGF gradients increase following VEGF overexpression; and
the arrangement of VEGF-overexpressing cells affects VEGF
gradients and VEGF receptor activation.
Materials and Methods
Numerical solution. Equations 1–14 were discretized using a fully
implicit ﬁnite difference algorithm in which ﬁrst-order spatial and
temporal derivatives were expressed with a forward difference
scheme and second-order spatial derivatives were expressed with a
central difference scheme. The algorithm uses an orthogonal grid
with uniform spacing in each spatial coordinate. A grid spacing of 1
lm was used; decreasing the grid spacing to 0.5 lm did not alter the
results. Areas of BM are identiﬁed by intersections between a grid
point in ECM and a grid point within a muscle ﬁber or capillary. The
BM thickness is about one-tenth of the grid size, thus its effect is
included in the lumped boundary condition (Equations 3–4 and
Equations 5–14). The model geometry implies that a BM must lie
between the two grid points and that every BM in the model is
discretized into a number of smaller BM areas equal to the total grid
intersections passing through every BM space in the model.
Discretized BM areas surrounding each capillary or muscle ﬁber are
assumed to be equal in size.
In this study we are interested in the steady state solution. At each
simulation step, free VEGF concentration was ﬁrst obtained using
Equations 1–6, and then binding, insertion, and internalization of
VEGF receptors at the cell surface and HSPG are solved independ-
ently using Equations 7–14. The model iterates until VEGF concen-
trations reach a steady state. The convergence criterion used was a
fractional change less than 10
 5 for VEGF120 and VEGF164 at each
grid point per step. The model is coded in Cþþ and requires
approximately one hour to reach a steady state solution on a 3.2-Ghz
Pentium IV processor with 1 GB of RAM.
Supporting Information
Figure S1. Total VEGF in Interstitial Space for Uniform Over-
expression
Found at DOI: 10.1371/journal.pcbi.0020127.sg001 (172 KB PDF).
Figure S2. VEGF Gradients for Uniform Overexpression
Found at DOI: 10.1371/journal.pcbi.0020127.sg002 (237 KB PDF).
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